Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Public biotech 2011—the numbers

Nature Biotechnology volume 30, pages 751–757 (2012)Cite this article

Subjects

The financial performance of the public biotech sector was remarkably buoyant last year, but a few worrying clouds hover on the horizon.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Public biotech barometers.
Figure 2: Public biotech companies by geographical location.
Figure 3: Global biotech industry financing.
Figure 4

Author information

Authors and Affiliations

  1. Brady Huggett is Business Editor at Nature Biotechnology,

    Brady Huggett

  2. Riku Lähteenmaki is a freelance writer in Turku, Finland.,

    Riku Lähteenmaki

Authors
  1. Brady Huggett
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Riku Lähteenmaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Supplementary information

Supplementary Text and Figures

Supplementary Table 1 (XLS 153 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huggett, B., Lähteenmaki, R. Public biotech 2011—the numbers. Nat Biotechnol 30, 751–757 (2012). https://doi.org/10.1038/nbt.2320

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2320

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research